Bulls REASONS TO BUY
Bears REASONS TO SELL
December 06, 2013
(Jutia Group, 12/2/13)
[at Seeking Alpha] - Remicade, one of the most potent drugs available on the market for treating arthritis, is currently...(read more)
(Jutia Group, 12/6/13)
[at Forbes] - This morning, Credit Suisse increased its price target on shares of Johnson & Johnson (JNJ) to $94 as growth from Invokana is expected to be better than originally expected....(read more)
(The DIV-Net, 11/13/13)
-Seven Year Average Revenue Growth Rate: 4.2% -Seven Year Average EPS Growth Rate: 1.6% -Seven Year Average Dividend Growth Rate: 9.4% -Current Dividend Yield: 2.83% -Balance Sheet Strength:...(read more)
JOHNSON & JOHNSON (JNJ) Company Overview
health care products, with 2010 annual sales of $61.6 billion, a decline of 0.5% from 2009. The company holds a significant share of the consumer and pharmaceutical markets, and is the world's largest developer and manufacturer of medical treatment and diagnostic devices.
The consumer health market size is increasing as consumers are taking greater responsibility and interest in their own health. Johnson & Johnson owns highly successful brands such as Tylenol, Band-Aid, and Neutrogena. The acquisition of Pfizer's Consumer Healthcare division in 2006 and addition of brands such as Listerine, Lubriderm, Visine, and Neosporin further solidified Johnson & Johnson dominance in consumer health care. Recently however the company has been plagued by a series of product-quality problems, mainly at its McNeil Consumer Healthcare unit, which makes over-the-counter medicines. The company has recalled Tylenol, Motrin, Benadryl and other products for problems ranging from musty odors that caused nausea in consumers, to excessive concentrations of active ingredients.  The problems with manufacturing have hurt the company's bottom line. In 2010, the company suffered significant losses in this segment with a decrease of 7.7% in revenue over the previous year. 
The company's pharmaceutical segment faces many of the challenges that face all pharmaceutical companies, including issues surrounding patent expiration and FDA approval. Johnson & Johnson's pharmaceutical segment maintained its revenue numbers as seen in 2009 with only a 0.6% decline in 2010.(Read more at Wikinvest )
What's in this JNJ analysis on Wikinvest...